MiMedx Group Inc (MDXG)

12.41
0.07 0.57
NASDAQ : Health Care
Prev Close 12.34
Open 12.24
Day Low/High 11.10 / 12.58
52 Wk Low/High 6.64 / 12.83
Volume 6.46M
Avg Volume 1.60M
Exchange NASDAQ
Shares Outstanding 112.47M
Market Cap 1.48B
EPS 0.10
P/E Ratio 69.26
Div & Yield N.A. (N.A)

Latest News

Finding Bullish and Bearish Stock Reversals

Finding Bullish and Bearish Stock Reversals

These stocks have changed direction recently.

MiMedx Reiterates Its Third Quarter Revenue Expectation To Exceed $80 Million Despite Hurricane Irma

MiMedx Reiterates Its Third Quarter Revenue Expectation To Exceed $80 Million Despite Hurricane Irma

MiMedx Production Operations and Placenta Recovery Functions Operating Normally

MiMedx Reports MultiCenter Randomized Controlled VLU Clinical Study Accepted For Publication In The International Wound Journal

MiMedx Reports MultiCenter Randomized Controlled VLU Clinical Study Accepted For Publication In The International Wound Journal

Unparalleled Results of 60% healing at 12 Weeks and 71% Healing at 16 Weeks Expected to Expand VLU Insurance Coverage to an Additional $75 Million to $150 Million in annual Revenue Opportunity

MiMedx Initiates Phase 3 Plantar Fasciitis Clinical Trial

MiMedx Initiates Phase 3 Plantar Fasciitis Clinical Trial

MIMEDX TO HOST SHAREHOLDER CALL ON AUGUST 7, 2017 TO PRESENT THE STATUS OF VARIOUS CLINICAL STUDIES SUPPORTING ITS BIOPHARMACEUTICAL STRATEGY

March 2018 Options Now Available For MiMedx Group (MDXG)

Investors in MiMedx Group Inc saw new options become available today, for the March 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

MiMedx Spikes After Q2 Earnings Beat; Mylan Pops on New Breast Cancer Drug -Biotech Movers

MiMedx Spikes After Q2 Earnings Beat; Mylan Pops on New Breast Cancer Drug -Biotech Movers

Here's what moving in the world of Biotech

MiMedx Announces That Its Second Quarter Revenue Exceeds The Guidance Range

MiMedx Announces That Its Second Quarter Revenue Exceeds The Guidance Range

Q2 2017 REVENUE OF $76.4 MILLION IS 33% INCREASE OVER Q2 2016

MiMedx Group Stock Sees Short Interest Decline 11%

MiMedx Group Stock Sees Short Interest Decline 11%

The most recent short interest data has been released for the 06/30/2017 settlement date, which shows a 2,488,401 share decrease in total short interest for MiMedx Group Inc , to 20,263,818, a decrease of 10.94% since 06/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

First Week of August 18th Options Trading For MiMedx Group (MDXG)

Investors in MiMedx Group Inc saw new options become available this week, for the August 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MDXG options chain for the new August 18th contracts and identified one put and one call contract of particular interest.

Scientific And Clinical Review Confirms Potential Of MiMedx DHACM Allografts For Regenerative Applications In Orthopedics

dHACM Allografts Retain Growth Factors And Bioactive Proteins Shown To Regulate Activity Of Cell Types, Including Stem Cells, That Are Critical To Orthopedic Repair Of Injured And Diseased Tissue

TheStreet Quant Rating: B (Buy)